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Abstract
The Birt-Hogg-Dube disease occurs as a result of germline mutations in the human Folliculin gene (FLCN), and is
characterized by clinical features including fibrofolliculomas, lung cysts and multifocal renal neoplasia. Clinical and genetic
evidence suggest that FLCN acts as a tumor suppressor gene. The human cell line UOK257, derived from the renal cell
carcinoma of a patient with a germline mutation in the FLCN gene, harbors a truncated version of the FLCN protein.
Reconstitution of the wild type FLCN protein into UOK257 cells delays cell cycle progression, due to a slower progression
through the late S and G2/M-phases. Similarly, Flcn–/– mouse embryonic fibroblasts progress more rapidly through the cell
cycle than wild type controls (Flcnflox/flox). The reintroduction of tumor-associated FLCN mutants (FLCN DF157, FLCN 1–469
or FLCN K508R) fails to delay cell cycle progression in UOK257 cells. Additionally, FLCN phosphorylation (on Serines 62 and
73) fluctuates throughout the cell cycle and peaks during the G2/M phase in cells treated with nocodazole. In keeping with
this observation, the reintroduction of a FLCN phosphomimetic mutant into the UOK257 cell line results in faster
progression through the cell cycle compared to those expressing the wild type FLCN protein. These findings suggest that
the tumor suppression function of FLCN may be linked to its impact on the cell cycle and that FLCN phosphorylation is
important for this activity. Additionally, these observations describe a novel in vitro assay for testing the functional
significance of FLCN mutations and/or genetic polymorphisms.
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Introduction
Individuals with a germline mutation in the FLCN gene have a
high lifetime risk for developing multiple and bilateral renal cell
carcinomas of any histologic type, fibrofolliculomas of the skin,
and lung cysts that can lead to spontaneous pneumothorax. This
constellation of lesions is known as Birt-Hogg-Dube (BHD)
syndrome [1,2,3,4,5,6,7].
The gene responsible for the BHD syndrome, FLCN, was
identified by linkage analysis and recombination mapping in BHD
families [8]. Clinical and genetic evidence indicate that FLCN acts
as a tumor suppressor gene. Analysis of renal cell carcinomas from
BHD patients reveals either loss of the wild type allele or a second,
somatic mutation that inactivates the wild type allele [9,10].
Deletion of the Flcn gene in the kidneys of transgenic mice leads to
the development of renal cysts and renal cell carcinoma
[11,12,13]. In addition, the reintroduction of the wild type (WT)
FLCN protein into the FLCN-deficient human renal cell
carcinoma cell line UOK257 suppresses their growth as colonies
in soft agar and restricts their growth as tumors when xenografted
in SCID mice [14,15].
FLCN consists of 14 exons and encodes an evolutionarily
conserved, nuclear and cytoplasmic, 64 kDa phosphoprotein,
folliculin (FLCN), which is ubiquitously expressed in adult and
embryonic tissues and has no obvious functional domains
[8,16,17,18]. Little is known about the biochemical function(s) of
the FLCN tumor suppressor protein. Cytoplasmic FLCN interacts
with Folliculin Interacting Proteins 1 and 2 (FNIP1 and FNIP2) in
a phosphorylation-dependent manner, and together they enter
complexes containing AMPK [16,19,20]. The functional outcome
of this biochemical interaction and the mechanistic details of
FLCN-FNIP-AMPK signaling remain unclear. Opposing data
have been provided indicating that FLCN down-regulates [11,16]
or up-regulates [13,21] mTORC1 function in vitro and in vivo.
To understand how FLCN may restrict cell growth in vitro, we
investigated its effect on the cell cycle. We synchronized isogenic
derivatives of the human renal cell carcinoma cell line UOK257
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that express either WT FLCN, mutant FLCN, or the vector
(control) and we studied their progression through the cell cycle.
Here we provide evidence that WT, but not tumor-associated
FLCN mutants, delay cell cycle progression through the late S and
G2/M phase. Similarly, mouse embryonic fibroblasts (MEFs)
lacking the Flcn gene progressed more rapidly through the cell
cycle than control MEFs expressing WT Flcn. During these studies
we observed that FLCN phosphorylation fluctuates during the cell
cycle and that FLCN phosphorylation on serines 62 (S62) and 73
(S73) increases dramatically at the G2/M boundary. We further
showed that orderly phosphorylation of FLCN is required for its
effect on late S and G2/M progression. This paper describes a fast
assay for analyzing the function of the FLCN protein and it links
FLCN phosphorylation to cell cycle progression. Thus it provides
an investigational frame to further study the role of FLCN on cell
cycle regulation.
Materials and Methods
Cell lines
The UOK257 renal carcinoma cell line (a generous gift from
Drs. Marston Linehan and Laura Schmidt, NCI/NIH) was
originally derived from the clear cell renal tumor of a BHD patient
and was previously established and described [15,22]. The cells
were grown in Dulbecco’s Modified Eagle Medium (DMEM,
Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum
(Hyclone), penicillin, streptomycin and L-glutamine (Invitrogen,
Carlsbad, CA). Mycoplasma testing was performed regularly to
ensure that the cells were mycoplasma negative. The UOK257
cells were infected with retroviruses encoding for FLCN or FLCN
mutants and selected in 2.0 micrograms/ml of puromycin. MEF
cells were obtained from a genetically engineered conditional Flcn
knockout mouse, BHDflox/flox [12]. All mice were housed and
manipulated in an ethically and humane manner, according to
protocols approved by the Institutional Animal Care and Use
Committee (IACUC) of Van Andel Institute. The MEF cells were
spontaneously immortalized by serially passaging them, according
to the NIH 3T3 protocol [23,24], in DMEM GlutaMAX media
(Invitrogen) supplemented with 10% fetal bovine serum (Hyclone),
penicillin, streptomycin and L-glutamine (Invitrogen). The cells
were infected in vitro with adenovirus expressing Cre recombinase
and clones were screened for recombination as previously
described [12]. Cellular clones exhibiting 100% recombination
in the Flcn gene were used in cell cycle experiments and mock
infected clones were used as controls.
Plasmids
The human WT FLCN gene was generated from a HEK293
cDNA pool by PCR with oligonucleotides 59-GCGCGGATC-
CGCCACCATGAATGCCATCGTGGCTCTCTG-39 (forward)
and 59-GCGCGAATTCAGTTCCGAGACTCCGAGGCTG-
TG-39 (reverse). The PCR product was restricted with BamHI
and EcoRI and ligated into pBABE-puromycin vector plasmid.
Several mutant forms of FLCN were generated, including two
phosphomutants (phosphomimetic and phosphoinactivating) and
three tumor-associated mutants (FLCN 1–469, FLCN K508R,
and FLCN DF157). For the FLCN 1–469 mutant the reverse
oligonucleotide 59-GCGCGAATTCAACTGGTCACCA-
CAAACTCGTACT TG-39 was used. FLCN K508R mutant
was engineered by PCR mutagenesis of the wild type FLCN using
oligonucleotides 59-TCGTCTGCCTCAGGGAGGAGTGG-39
(forward) and 59-CCACTCCTCCCTGAGGCAGACGA-39 (re-
verse). FLCN DF157 mutant was engineered by PCR mutagenesis
of the wild type FLCN using oligonucleotides 59-AGCCA-
CACCTTCATCAAGGACAGC-39 (forward) and 59-GCTGTC-
CTTGATGAAGGTGTGGCT -39 (reverse). The FLCN S62A/
S73A and FLCN S62E/S73E phosphomutants were generated
using the following oligonucleotides: S62A, 59-CGTGCGCAC-
GCCCCCGCAGAG-39 and 59-CTCTGCGGGGGCGTGCGC
ACG-39; S62E, 59-CGTGCGCACGAGCCCGCAGAG-39 and
59-CTCTGCGGGCTCGT GCGCACG-39; S73A, 59-GAGTC-
CAGCGCCCCGGGGCCC-39 and 59-GGGCCCCGGGGC-
GCTGGACTC-39; S73E, 59-GAGTCCAGCGAGCCGGG-
GCCC-39 and 59-GGGCCCCGGCTCGCTGGACTC-39. Ret-
roviruses were produced by co-transfecting 293T cells as described
previously [25]. The media containing the virus was collected,
filtered and the UOK257 cells were infected by spin infection [26].
Western blots and antibodies
Protein expression was detected by Western blotting, as
described before [25]. In brief, for cell lysis, RIPA buffer
(25 mM TrisNHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS) containing protease and phosphatase
inhibitors (Trypsin Inhibitor, Leupeptin, Sodium Orthovanadate,
Pepstatin A, Aprotinin, Sodium Fluoride, and PMSF) was used.
Proteins were separated by SDS-PAGE electrophoresis, trans-
ferred to a PVDF membrane and detected with the cognate
antibody. The following antibodies were used: anti-Pan Actin
(Neomarkers, Fremont, CA); anti-FLCN antibody (FLCN
(D14G9) Rabbit mAb #3697; Cell Signaling Technology,
Danvers, MA). The antigen recognized by the anti-human FLCN
antibody maps to amino acids 301–430 (data not shown). For
protein stability experiments, cells were treated with 10 mg/ml of
cycloheximide and collected over the course of 8 hours.
Cell fractionation
The UOK257 cells were gently lysed in a hypotonic solution
on ice for 15 minutes. The nuclei were pelleted (30 sec at
184006g) and the supernatant containing the cytosolic fraction
was collected. The nuclear fraction was isolated by resuspending
the remaining cell pellet in a high salt solution (20 mM Tris-HCl
pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM CaCl2, 300 mM
sucrose, and 0.1% Triton X-100) and rotating for 15 minutes at
4uC. The solution was centrifuged at 184006g for 5 minutes and
the supernatant containing the nuclear fraction was collected.
Post-translational modifications detection by LC-MS/MS
In gel digestion. FLCN was immunoprecipitated from cells
arrested in G2/M by nocodazole (50 ng/ml for 14–16 hours)
and resolved in SDS-PAGE. Gels were stained with Coomassie
Blue and FLCN bands subjected to in-gel tryptic digestion for
18 hours at 37uC. Liquid Chromatography – Mass Spectrometry. The
protein digests were analyzed by capillary reversed phase liquid
chromatography (RPLC), on-line coupled to a hybrid LTQ2FT
MS (Thermo Fisher Scientific, San Jose, CA). The nano-RPLC
system was composed of an Ultimate 3000 nano2LC pump
(Dionex, Sunnyvale, CA), a 75 mm i.d. 15 cm analytical column
packed with 3 mm i.d. Magic C18AQ, 200 A˚ pore size particles,
with a flow rate of 200 nl/minute. MS data were collected in the
data dependent mode. MS scans were acquired from m/z 400 to
2000 with a mass resolution of 100,000 at m/z 400, with up to
26106 ions and a normalized collision energy of 35%. Data
Processing: The DTA files were generated from acquired raw files
by ExtractMSn program (Version 4.0, Thermo Fisher Scientific),
converted to Mascot generic format and searched against the
human SwissProt database using the Mascot algorithm (ver. 2.2,
MatrixScience, Boston, MA). Cysteine carbamidomethylation was
included as a fixed modification while phosphorylation of S, T, or
Folliculin Delays Cell Cycle Progression
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e66775
Figure 1. FLCN delays progression through the late S and the G2/M phases of the cell cycle. (A) Representative cell cycle profiles of
UOK257 cells infected with retroviruses expressing the vector only or WT FLCN. Progression through the cell cycle was measured by propidium iodide
(PI) labeling of synchronized cells collected at 0, 4, 8 and 12 hours after release from thymidine block. (B) FLCN-deficient UOK257 cells (squares and
dashed line) and their isogenic counterparts reconstituted with wild type (WT) FLCN (triangles and solid line) were synchronized by double thymidine
block and their progression through cell cycle after release was analyzed by FACS. Vertical axis indicates the percent of all cells registering in that
specific phase of cell cycle. Horizontal axis indicates hours post release from thymidine. The average of three experiments is presented (n = 3),
* indicates a statistically significant difference (t test, p,0.05), bars correspond to standard error of the mean (SEM).
doi:10.1371/journal.pone.0066775.g001
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Y was considered a variable modification. Full tryptic enzyme
specificity was applied with up to two missed cleavage sites.
Precursor mass tolerance was set to 30 ppm with correction for up
to two 13C isotopes to account for incorrectly assigned mono-
isotopic peaks, and 0.7 Da was the tolerance for the fragment ions.
MS/MS spectra assigned to human FLCN peptides with
phosphorylation were inspected manually to determine the exact
site of modification.
Cell synchronization and cell cycle progression analysis
Cells were synchronized using nocodazole or a double
thymidine block. Sub-confluent cells were treated with nocodazole
(50 ng/ml) for 14–16 hours and only the mitotic cells were
collected. For cell cycle progression analysis, cells were grown to
about 20–30% confluence in 6 well dishes. Cells were arrested at
G1/S by treatment with 2 mM thymidine for 18 hours. The cells
were then released by washing with PBS and grown in DMEM for
9 hours. For the second block, cells were treated with thymidine
(2 mM) for 17 hours. Double blocked cells were released by
washing with PBS and adding fresh medium. Cell cycle
progression was measured using the Click-it EdU Flow Cytometry
Assay Kit (used according to manufacturer’s instructions, Invitro-
gen). The samples were processed and analyzed using a BD LSR
II Flow Cytometer System and BD FACSDiva software (BD
Biosciences, San Jose, CA).
Results
Genetic evidence suggests that FLCN acts as a tumor suppressor
gene. Since several tumor suppressor genes affect the cell cycle, we
sought to investigate the potential role of FLCN on cell cycle
progression. In order to investigate the cellular functions of FLCN,
we used the human cell line UOK257, which was generated from
the renal cell carcinoma of a BHD patient and expresses a
truncated, putatively null form of the FLCN protein. The
UOK257 cells were infected with retroviruses that express WT
human FLCN or the empty vector (control; FLCN null). The
effect of FLCN reconstitution on cell cycle progression was
determined by comparing the cell cycle profiles (both propidium
iodide staining (Figure 1A) and EdU uptake (Figure 1B)) of these
two isogenic cell lines following synchronization with a double
thymidine block. FLCN WT reconstitution resulted in a statisti-
cally significant delay in progression through the late S phase (6–
8 hours after release from thymidine treatment), which continued
during the G2 and M phases (8–12 hours) of the cell cycle
(Figure 1A and 1B). The FLCN null cells (UOK257 vector only)
progressed more rapidly through the cell cycle (late S phase at 4–
6 hours and G2/M phases at 6–10 hours after release from
thymidine; Figures 1A and 1B). There was no difference in the
response of FLCN deficient or FLCN WT reconstituted cells to
thymidine block and both populations arrested similarly in G1
(Figure 1B, 0 hour time point).
Figure 2. MEF cells lacking the Flcn gene progress more rapidly through the cell cycle. MEF cells with a floxed copy of the Flcn gene
(Flcnflox/flox; circles and solid line) and MEF cells null for Flcn following Cre recombinase mediated excision and recombination (Flcn–/–; squares and
dashed line) were synchronized by double thymidine block. FACS analysis was used to determine the percentage of cells in each stage of the cell
cycle (y axis) over the course of 12 hours (x axis). Error bars indicate SEM from three experiments (n = 3), * indicates a statistically significant difference
(t test, p,0.05).
doi:10.1371/journal.pone.0066775.g002
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To confirm these results in a second, non-transformed cell line,
we immortalized MEF cells homozygous for a floxed copy of the
Flcn gene (Flcnflox/flox). Flcn knockout cells (Flcn–/–) were obtained
by infecting the Flcnflox/flox MEFs in vitro with adenoviruses
expressing Cre recombinase. MEF cells lacking the Flcn tumor
suppressor gene (Flcn–/–) progressed more rapidly through G1,
early S, late S and G2/M than Flcnflox/flox MEFs (Figure 2).
To investigate whether FLCN’s effect on cell cycle progression
is linked to its tumor suppressor activity, the FLCN null UOK257
cells were reconstituted with either a tumor-associated FLCN
missense point mutant (K508R), a tumor-associated FLCN
truncation mutant (amino acids 1–469), or a tumor-associated
FLCN in-frame deletion (DF157). These mutations have been
detected in the germline of BHD patients and have been linked to
the development of fibrofolliculomas, pneumothorax and renal cell
carcinoma [10,27,28]. FLCN K508R is expressed at levels
comparable to the exogenously expressed WT FLCN, while the
truncating mutants FLCN 1–469 and FLCN DF157 display
decreased stability (Figure 3A), which is in agreement with
previously reported data demonstrating reduced protein stability
for tumor-associated FLCN truncating mutants [29]. All of the
tumor-associated mutants fail to delay cell cycle progression
through the S and G2/M phases (Figure 3B–E), suggesting a
genetic link between FLCN’s tumor suppressor function and its
ability to control cell cycle progression.
Following our observation that the loss of WT FLCN results in
faster progression through the cell cycle, we examined changes in
the level of FLCN protein expression during the cell cycle. No
significant changes in FLCN expression were detected during the
first 8 hours after release from the double thymidine block (G1
through to late S phase), but the formation of slow migrating
FLCN species was detected at the time corresponding to late G2
phase (data not shown). To further investigate changes in
endogenous FLCN expression during the late G2 phase, we
arrested U2OS osteosarcoma cells at the G2/M boundary with
nocodazole. U20S cells endogenously express WT FLCN, which
appears as a doublet by Western blot. During mitosis (immedi-
Figure 3. Tumor-associated FLCN mutations fail to delay cell
cycle progression. (A) Expression of exogenous FLCN in UOK257 cells
infected with retroviruses harboring empty vector control, FLCN WT,
FLCN DF157, FLCN K508R, or FLCN 1–469. (B) Cell cycle profiles of the
UOK257 cells and the isogenic cell lines expressing empty vector
control, FLCN WT, FLCN DF157, FLCN K508R, or FLCN 1–469,
demonstrating the amount of cells in the G1, S and G2/M stages as
determined by PI staining. The experiment was repeated three times
(n = 3), but only one representative image of the cell cycle profile,
12 hours after release from thymidine block, is shown. (C) Tumor-
associated FLCN truncated mutant 1–469 fails to delay cell cycle
progression. FLCN deficient UOK257 cells (black dashed line) and their
isogenic counterpart reconstituted with FLCN WT (red line) or FLCN 1–
469 mutant (blue line) were synchronized by double thymidine block
and released. Progression through the cell cycle was analyzed by FACS.
Vertical axis indicates the percentage of all cells registering in the
specific phase of cell cycle. Horizontal axis indicates hours post
thymidine release. (D) Tumor-associated FLCN missense mutant K508R
fails to delay cell cycle progression. Same as in (C), except that the
reconstituted mutant is FLCN K508R (green line). (E) Tumor-associated
FLCN deletion mutant DF157 fails to delay cell cycle progression. Same as
in (C) and (D), except that the reconstituted mutant is FLCN DF157
(purple line). The average of three experiments is presented (n = 3) in
each panel; * indicates a significant difference between UOK257+ vector
only compared to UOK257+ FLCN WT; # indicates a difference between
UOK257 FLCN WT and the UOK257+ tumor-associated mutant (1–469,
K508R, or DF157); $ indicates a difference between UOK257+ vector
only cells and the UOK257 cells expressing a tumor-associated mutant
(One way ANOVA, Tukey’s post-test, p,0.05). Error bars correspond to
SEM.
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PLOS ONE | www.plosone.org 5 July 2013 | Volume 8 | Issue 7 | e66775
ately following nocodazole treatment), there was a shift in the
Western blot banding pattern, and the FLCN protein was mainly
detected in the top band of the doublet, which migrates with
slower mobility (Figure 4A). This slow migration is likely due to
phosphorylation of FLCN since treatment of the mitotic cell
protein lysates with phosphatase attenuates the expression of this
slower FLCN species (Figure 4A). To determine if FLCN
phosphorylation is altered during the cell cycle, especially during
the G2 and M phases, we replated the mitotic cells and
examined FLCN expression at specific time intervals after
mitosis. The Western blot data demonstrated that endogenous
FLCN phosphorylation changed over time and returned to
baseline following exit from mitosis, which occurs in about 1.5–
2 hours after release from nocodazole (Figure 4B). Enhancement
of FLCN phosphorylation at the G2/M boundary is not a cell
type specific phenomenon; it has been detected in the U20S,
HeLa and UOK257 cell lines (Figure 5D, and data not shown).
To identify the residues that are phosphorylated at the G2/M
boundary, we immunoprecipitated endogenous FLCN from
asynchronous or nocodazole arrested U2OS cells. The precipitates
were resolved in SDS-PAGE gels and the FLCN protein was
detected by size using Coomassie Blue staining (Figure 5A). The
lower (Figure 5A, open arrow) and the upper (Figure 5A, filled
arrow) migrating FLCN bands were excised separately and in gel
digested with trypsin. The post-translational modifications of the
peptides were analyzed by liquid chromatography, followed by
mass spectrometry analysis (Figure 5B). The upper band
(phosphorylated FLCN) was significantly enriched in peptides
phosphorylated at Serines 62 and 73 (S62 and S73). FLCN
phosphorylation on serine 62 was previously reported [17,18], but
these phosphorylation sites have never been associated with
changes in cell cycle progression.
To confirm that phosphorylation on serine 62 and serine 73 is
responsible for the shift in the FLCN banding pattern during G2/
M transition, we engineered a phosphomimetic FLCN mutant
(FLCN S62/73E) and a phosphoinactivating mutant (FLCN S62/
73A). Both phosphomutants (FLCN S62/73E or FLCN S62/73A)
were stably expressed in the FLCN-deficient UOK257 cells and
were detected in both the cytosol and the nucleus, similarly to WT
FLCN (Figure 5C). The FLCN serine to alanine mutant that is
unable to undergo phosphorylation on Serines 62 and 73 (FLCN
S62/73A) did not shift upwards in nocodazole arrested cells, while
the phosphomimetic serine to glutamic acid mutant (FLCN S62/
73E) constitutively migrated more slowly than WT FLCN and its
migration (banding pattern) was not affected by nocodazole
treatment (Figure 5D). Interestingly, the in-frame, tumor-associ-
ated FLCN DF157 mutant, was also phosphorylated during
mitosis, although to a lesser degree than the FLCN WT protein
(Figure 5D). In order to determine if phosphorylation of FLCN on
S62 and S73 affects stability of the protein, we grew U20S cells
either asynchronously or arrested at G2/M and inhibited de novo
protein synthesis with cycloheximide (Figure 5E). Endogenous
FLCN is a relatively stable protein with a half-life of approximately
6–8 hours (Figure 5E). The intensity of the phosphorylated form of
the FLCN protein (upper band in nocodazole arrested cells)
diminished prior to the dephosphorylated form (lower band) at the
4–6 hours time points, suggesting that FLCN S62/S73 phosphor-
ylation has reduced stability (Figure 5E).
Lastly, we tested the ability of the phosphomutants (FLCN S62/
73E or FLCN S62/73A) to delay cell cycle progression through
the late S and G2/M phases. Phosphomimetic mutations (FLCN
S62/73E) fail to delay cell cycle progression and exhibited a
similar cell cycle profile as the FLCN deficient vector only controls
(Figure 6A and B). This effect was most pronounced and reached
statistical significance at the 12-hour time point of G2/M
(Figure 6B). In contrast, the phosphoinactivating mutations (FLCN
S62/73A) partially delayed progression through the cell cycle,
similarly to the cells expressing WT FLCN (Figure 6A and C).
These data suggest that orderly phosphorylation of FLCN occurs
during the G2/M phases of the cell cycle and is required for the
normal cellular functions of FLCN. In addition, our results
demonstrate that, with regards to cell cycle, phosphorylation of
FLCN on serines 62 and 73 results in an inactive form of the
protein.
Discussion
The FLCN gene encodes for a tumor suppressor phospho-
protein that localizes to the nucleus and the cytoplasm, but the
biochemical mechanisms of FLCN function are currently
unknown. In keeping with the physiology of many tumor
suppressor genes, we hypothesized that FLCN affects cell cycle
progression. The data presented herein demonstrate that FLCN
deficient UOK257 cells progress more rapidly through the cell
cycle compared to cells expressing WT FLCN. The difference
between FLCN deficient and reconstituted UOK257 cells is
maximal during the late S and G2/M phases of cell cycle, but it
is unclear whether this reflects a primary delay during the late S
phase or if FLCN affects both of these phases independently.
Mutations in the FLCN gene associated with kidney tumorigen-
esis fail to slow cell cycle progression, suggesting a link between
cell cycle progression and the tumor suppressor function of
FLCN.
Figure 4. FLCN is hyperphosphorylated during cell cycle
progression from G2 to M. (A) A slower migrating FLCN band is
detected in cells arrested at the G2/M boundary and is likely the result of
phosphorylation. The expression of endogenous human FLCN in
nocodazole arrested, mitotic (M) U20S cells was analyzed by FLCN
immunoblot after a 2 hour incubation with vehicle only (M+V),
phosphatase (M+ Ph), or in the presence of phosphatase along with
phosphatase inhibitors (M+ Ph +I). U20S cells growing asynchronously
(Asy) were used as a control (hypophosphorylated). (B) FLCN
phosphorylation decreases upon exit from mitosis. U2OS cells arrested
by nocodazole in G2/M were collected by mitotic shake and replated.
FLCN expression was detected by Western blot at increasing time
intervals post-replating (time indicated on the horizontal axis). Actin is
used as a loading control.
doi:10.1371/journal.pone.0066775.g004
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FLCN function has been tested in classic tumor suppressor
assays, such as soft agar colony formation and tumor growth in
mouse xenograft assays [14,15,29]. Testing FLCN species (such as
tumor-associated mutants and phosphomutants) in the cell cycle
progression assay we present here is an additional, significantly
faster method, to differentiate between putative mutant forms and
polymorphisms. Although the majority of FLCN germline
mutations predict for a truncated form of the protein, missense
mutations (such as K508R) and polymorphisms have been
reported [10,30,31,32]. In addition, this rapid in vitro assay can
provide a reporter assay for testing the functional significance of
putative FLCN interacting proteins and therefore accelerate
insight into the biochemical functions of FLCN.
FLCN is an evolutionarily conserved protein and knocking out
the mouse ortholog in mouse kidneys resulted in hyperplasia and
tumorigenesis [11,12,13]. Analysis of the renal hyperplasia and
tumors in Flcn knockout mice revealed increased cellular
proliferation, but the cell cycle changes underlying this phenotype
were not addressed [11]. Increased proliferation rate may be due
to shortening of any or all phases of the cell cycle, or more rapid
exit from quiescence. Here we show specifically, in both the MEF
Flcn–/– and the UOK257 cells, that WT FLCN delays progression
of cell cycle through the late S and G2/M phases. The ability of
FLCN to alter cell cycle progression in both human and mouse
cells further suggests that the tumor suppressor activity of FLCN is,
at least in part, mediated by its ability to affect cell cycle
progression.
Similarly to the phosphorylation activity of other cell cycle
regulating tumor suppressor proteins, such as Rb and p53
[33,34,35], we observed that FLCN phosphorylation changes
during the cell cycle. Phosphorylation of FLCN increases as cells
progress through the G2/M checkpoint and returns to basal levels
(equivalent to asynchronous cells) after exit from mitosis. Our
results demonstrate that orderly changes in FLCN phosphoryla-
tion at different stages of the cell cycle are linked to FLCN’s ability
to slow progression through the late S and G2/M stages of the cell
cycle. The introduction of the phosphomimetic FLCN S62/73E
mutant into FLCN-deficient cells produces a G2/M transition
phenotype resembling the null (UOK257 vector only) cells. In
contrast, the S62/73A phosphoinactivating mutant leads to an
intermediate phenotype between wild type and null. These
Figure 5. Identification of FLCN phosphorylation sites at the
G2/M boundary. (A) U2OS cells were cultured in the presence (lane 2)
or absence (lane 1) of nocodazole overnight and immunoprecipitated
FLCN protein was detected by Coomassie Blue staining of SDS-PAGE
gels. (B) LC-MS/MS analysis of FLCN peptides. Extracted ion chromato-
grams for FLCN peptide AHSPAEGASVESSSPGPK with no phosphoryla-
tion (a), one phosphorylation (b) and 2 phosphorylation sites (c).
Intensity corresponds to the absolute intensity of the highest peak in
the chromatogram. No normalization was performed. (C) FLCN deficient
UOK257 cells were reconstituted with FLCN WT, FLCN double
phosphoinactivating mutant S62/73A or FLCN double phosphomimetic
mutant S62/73E. Exogenous WT FLCN and the phosphomutants (S62/
73A and S62/73E) are expressed in both the nuclear and the
cytoplasmic cellular fractions. (D) FLCN deficient UOK257 cells and the
isogenic cell lines reconstituted with either FLCN WT, a tumor-
associated mutant (FLCN DF157) or the phosphomutants (S62/73A
and S62/73E) were cultured overnight in the absence or presence of
nocodazole. (E) UOK257 FLCN WT cells growing asynchronously (Asyn)
or arrested during G2/M with nocodazole were treated with either
DMSO or cycloheximide (10 mg/ml). Protein stability was determined by
Western blot at various time points over the course of 8 hours (V –
UOK257 vector only cells; WT – UOK257 FLCN WT cells). Lysates were
resolved in SDS-PAGE and FLCN protein detected with anti-FLCN
antibody. Actin serves as a loading control.
doi:10.1371/journal.pone.0066775.g005
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differences are consistent, highly reproducible and telling of a
biological phenomenon, namely the requirement of orderly
phosphorylation followed by dephosphorylation to fulfill the wild
type function. Phosphomimetic mutants (StoE) are inactive with
regards to G2/M transition. Consistent with this hypothesis is the
observation that the hyperphosphorylated form has a shorter
protein half-life. The StoA mutant is partially active (presumably
during early/mid S) but possibly fails to execute wild type
functions related to G2/M. Since cells reconstituted with the
FLCN phosphomutants displayed similar expression levels and
cellular localization patterns as those reconstituted with WT
FLCN, it is likely that phosphorylation of FLCN directly affects its
ability to interact with partner proteins and activate signaling
pathways. These interactions may occur in either the nuclear and/
or cytoplasmic compartments of the cell.
In summary, these data demonstrate a novel function of the
tumor suppressor protein FLCN on cell cycle progression and
pinpoints this effect to the late S and G2/M phases. The biologic
significance of this observation is supported by the findings that
cells expressing tumor-associated FLCN mutants fail to exhibit a
delay cell cycle progression. In addition, we show that the
phosphorylation of FLCN changes during the cell cycle, and is
likely responsible for FLCN’s role in cell cycle regulation.
Aknowledgments
We would like to thank Dr. Marina Hincapie and Dr. Michael Zimmer for
assistance with experiments, Dr. Ravi Mylvaganam of the MGH Flow
Cytometry Core for assistance with flow cytometry and Dr. Nicholas
Dyson for critically reading the manuscript.
Author Contributions
Conceived and designed the experiments: LAL OI. Performed the
experiments: LAL PH JW JK CN. Analyzed the data: LAL OI TR.
Contributed reagents/materials/analysis tools: BK BTT TR. Wrote the
paper: LAL OI.
References
1. Birt AR, Hogg GR, Dube WJ (1977) Hereditary multiple fibrofolliculomas with
trichodiscomas and acrochordons. Arch Dermatol 113: 1674–1677.
2. Khoo SK, Bradley M, Wong FK, Hedblad MA, Nordenskjold M, et al. (2001)
Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to
chromosome 17p12-q11.2. Oncogene 20: 5239–5242.
3. Menko FH, van Steensel MA, Giraud S, Friis-Hansen L, Richard S, et al. (2009)
Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 10:
1199–1206.
4. Roth JS, Rabinowitz AD, Benson M, Grossman ME (1993) Bilateral renal cell
carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 29: 1055–
1056.
5. Scalvenzi M, Argenziano G, Sammarco E, Delfino M (1998) Hereditary
multiple fibrofolliculomas, trichodiscomas and acrochordons: syndrome of Birt-
Hogg-Dube. J Eur Acad Dermatol Venereol 11: 45–47.
6. Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, et al. (2001)
Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous
pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum
Genet 69: 876–882.
7. Toro JR, Glenn G, Duray P, Darling T, Weirich G, et al. (1999) Birt-Hogg-
Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135: 1195–
1202.
8. Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, et al. (2002)
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign
tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome.
Cancer Cell 2: 157–164.
9. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, et al. (2005)
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of
families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76: 1023–1033.
10. Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, et al. (2008) BHD
mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube
syndrome: a new series of 50 families and a review of published reports. J Med
Genet 45: 321–331.
11. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, et al. (2008) Kidney-
targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-
mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer
Inst 100: 140–154.
12. Chen J, Futami K, Petillo D, Peng J, Wang P, et al. (2008) Deficiency of FLCN
in mouse kidney led to development of polycystic kidneys and renal neoplasia.
PLoS One 3: e3581.
13. Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, et al. (2009)
The role of the Birt-Hogg-Dube protein in mTOR activation and renal
tumorigenesis. Oncogene 28: 1594–1604.
14. Hong SB, Oh H, Valera VA, Stull J, Ngo DT, et al. (2010) Tumor suppressor
FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates
expression of key molecules in TGF-beta signaling. Mol Cancer 9: 160.
15. Yang Y, Padilla-Nash HM, Vira MA, Abu-Asab MS, Val D, et al. (2008) The
UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dube
gene pathway. Cancer Genet Cytogenet 180: 100–109.
16. Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, et al. (2006)
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1,
and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad
Sci U S A 103: 15552–15557.
17. Piao X, Kobayashi T, Wang L, Shiono M, Takagi Y, et al. (2009) Regulation of
folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway.
Biochem Biophys Res Commun 389: 16–21.
18. Wang L, Kobayashi T, Piao X, Shiono M, Takagi Y, et al. (2010) Serine 62 is a
phosphorylation site in folliculin, the Birt-Hogg-Dube gene product. FEBS Lett
584: 39–43.
19. Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, et al. (2008) Identification
and characterization of a novel folliculin-interacting protein FNIP2. Gene 415:
60–67.
20. Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, et al. (2008) Interaction of
folliculin (Birt-Hogg-Dube gene product) with a novel Fnip1-like (FnipL/Fnip2)
protein. Oncogene 27: 5339–5347.
21. van Slegtenhorst M, Khabibullin D, Hartman TR, Nicolas E, Kruger WD, et al.
(2007) The Birt-Hogg-Dube and tuberous sclerosis complex homologs have
opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. J Biol
Chem 282: 24583–24590.
22. Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, et al. (2012) Regulation of
mitochondrial oxidative metabolism by tumor suppressor FLCN. J Natl Cancer
Inst 104: 1750–1764.
23. Todaro GJ, Green H (1963) Quantitative studies of the growth of mouse embryo
cells in culture and their development into established lines. J Cell Biol 17: 299–
313.
Figure 6. FLCN phosphomimetic mutations inactivate the effect of WT FLCN on cell cycle. (A) A FLCN phosphomimetic mutant (S62/73E)
results in more rapid progression through the cell cycle compared to the FLCN WT, while the FLCN phosphoinactivating mutant (S62/73A) retains the ability
to delay cell cycle progression. Representative cell cycle profiles from UOK257 cells and the isogenic UOK257 cells expressing FLCN WT, or the
phosphomutants S62/73E or S62/73A, collected 12 hours after release from thymidine. UOK257 cells expressing FLCN WT or S62/73A have more cells
in G2/M and fewer cells entering G1 compared to the FLCN null (vector only) and the S62/73E cells as measured by PI staining. (B) UOK257 (black line)
and their isogenic counterparts reconstituted with WT FLCN (red line) or FLCN S62/73E mutant (blue line) were synchronized by double thymidine
block. Cell cycle progression after release from thymidine was analyzed by FACS. Vertical axis indicates the percent of all cells registering in the
specific phase of cell cycle. Horizontal axis indicates hours post thymidine release. The average of three experiments is presented (n = 3) in each panel;
bars correspond to standard error of the mean (SEM). (C) Same as in (B), except that the reconstituted phosphomutant is FLCN S62/73A (purple line).
For both (B) and (C), * indicates a statistically significant difference between UOK257+ vector only compared to UOK257+ FLCN WT at the
corresponding time point; # indicates a difference between UOK257 FLCN WT and the UOK257+ phosphomutant (S62/73E or S62/73A); $ indicates a
difference between UOK257+ vector only and UOK257+ phosphomutant (S62/73E or S62/73A) (One-way ANOVA, Tukey’s post-test, p,0.05).
doi:10.1371/journal.pone.0066775.g006
Folliculin Delays Cell Cycle Progression
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e66775
24. Xu J (2005) Preparation, culture, and immortalization of mouse embryonic
fibroblasts. Curr Protoc Mol Biol Chapter 28: Unit 28 21.
25. Zimmer M, Ebert BL, Neil C, Brenner K, Papaioannou I, et al. (2008) Small-
molecule inhibitors of HIF-2a translation link its 5’UTR iron-responsive element
to oxygen sensing. Mol Cell 32: 838–848.
26. Danos O, Mulligan RC (1988) Safe and efficient generation of recombinant
retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad
Sci U S A 85: 6460–6464.
27. Ren HZ, Zhu CC, Yang C, Chen SL, Xie J, et al. (2008) Mutation analysis of
the FLCN gene in Chinese patients with sporadic and familial isolated primary
spontaneous pneumothorax. Clin Genet 74: 178–183.
28. van Steensel MA, Verstraeten VL, Frank J, Kelleners-Smeets NW, Poblete-
Gutierrez P, et al. (2007) Novel mutations in the BHD gene and absence of loss
of heterozygosity in fibrofolliculomas of Birt-Hogg-Dube patients. J Invest
Dermatol 127: 588–593.
29. Nahorski MS, Reiman A, Lim DH, Nookala RK, Seabra L, et al. (2011) Birt
Hogg-Dube syndrome-associated FLCN mutations disrupt protein stability.
Hum Mutat 32: 921–929.
30. Cho MH, Klanderman BJ, Litonjua AA, Sparrow D, Silverman EK, et al.
(2008) Folliculin mutations are not associated with severe COPD. BMC Med
Genet 9: 120.
31. Truong HT, Dudding T, Blanchard CL, Elsea SH (2010) Frameshift mutation
hotspot identified in Smith-Magenis syndrome: case report and review of
literature. BMC Med Genet 11: 142.
32. Woodward ER, Ricketts C, Killick P, Gad S, Morris MR, et al. (2008) Familial
non-VHL clear cell (conventional) renal cell carcinoma: clinical features,
segregation analysis, and mutation analysis of FLCN. Clin Cancer Res 14:
5925–5930.
33. Chen PL, Scully P, Shew JY, Wang JY, Lee WH (1989) Phosphorylation of the
retinoblastoma gene product is modulated during the cell cycle and cellular
differentiation. Cell 58: 1193–1198.
34. Stewart ZA, Pietenpol JA (2001) p53 Signaling and cell cycle checkpoints. Chem
Res Toxicol 14: 243–263.
35. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:
323–330.
Folliculin Delays Cell Cycle Progression
PLOS ONE | www.plosone.org 10 July 2013 | Volume 8 | Issue 7 | e66775
